Zymeworks (ZYME) 完成收购Theravance Biopharma,将YUPELRI纳入产品组合

· gurufocus.com

2026年9月28日,Zymeworks Inc(纳斯达克:ZYME)完成了对Theravance Biopharma的收购,将呼吸系统药物YUPELRI(revefenacin)纳入旗下。

On September 28, 2026, Zymeworks Inc (NASDAQ: ZYME) finalized its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI (revefenacin) to its ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI